Down Nearly 65% From Its 52-Week High, Has Rocket Lab Stock Become a Bargain Buy?

Rocket Lab shares fell 64% from a late-May peak of $151 to just under $54, amid reduced enthusiasm for space stocks following SpaceX’s IPO. The company reported record quarterly revenue of $234 million, up 62% year over year, and $769 million in trailing-12-month revenue, but remains unprofitable. Neutron’s initial launch has been delayed until next year; its planned payload capacity is up to 13,000 kg, or 15,000 kg for expendable missions.

Analysis

The selloff looks more like a sentiment and capital-allocation shock than evidence of deteriorating demand, but that does not by itself make RKLB cheap. At the article’s cited $34B market cap, the company is valued at roughly 44x trailing revenue—a multiple that leaves little room for Neutron schedule slippage, weak launch cadence, or dilution. The key valuation bridge is not payload capacity; it is reliable flights, customer commitments that convert to revenue, and cash consumption required to reach scale.

In the next 1–3 months, positioning may remain sensitive to launch-date updates and financing/cash-flow disclosures. Over 6–18 months, a successful Neutron program could broaden addressable missions, while delays or early reliability issues would extend investment needs and undermine the growth multiple. SpaceX’s scale creates a second-order risk: bundled rideshare capacity and pricing pressure could constrain economics even if overall space activity grows. Rocket Lab’s spacecraft and systems work may diversify revenue, but verify segment mix and margins rather than treating it as a proven hedge to launch volatility.

Contrarian point: the 64% drawdown is not a valuation floor; the market may be repricing execution risk that momentum-focused coverage underweights. Conversely, an IPO-related rotation out of space names could reverse quickly if Rocket Lab delivers milestones. Treat management timelines as claims until supported by independently observable test and launch progress.

Key Decisions for Investors

• Avoid treating the drawdown alone as a buy signal. For a high-risk growth sleeve, consider a small, staged RKLB position rather than a full allocation; add only after a credible Neutron schedule and funding/cash runway are confirmed.
• Keep a watchlist alert for Neutron test and launch milestones, quarterly cash burn, backlog conversion, and revenue/margin mix between launch and spacecraft systems. These determine whether growth is translating into scalable economics.
• Do not short solely on the valuation: a successful milestone could produce a sharp sentiment reversal. Reassess the thesis if schedules slip again, cash use accelerates without corresponding customer conversion, or guidance/backlog weakens.
• Monitor whether SpaceX pricing or bundled rideshare offerings pressure Rocket Lab’s bookings and realized economics; evidence of sustained pricing or win-rate deterioration would falsify the view that this is mainly sentiment-driven.